Introduction
The biotech and pharmaceutical sector is undergoing one of its most dynamic transformations in decades. From looming patent cliffs and aggressive mergers and acquisitions (M&A) activity to AI-driven drug discovery and landmark FDA approvals, investors tracking biotech stocks have much to watch in 2025 and 2026. Among the most closely followed names are Merck (MRK), Bristol-Myers Squibb (BMY), Amgen (AMGN), and Gilead Sciences (GILD) — four industry giants navigating both significant challenges and exciting opportunities.
Why Biotech and Pharma Stocks Matter Now
The biopharma sector is at a critical crossroads. A staggering $173.9 billion patent cliff is expected to materialize by 2032 as blockbuster drugs lose exclusivity, forcing pharmaceutical companies to aggressively expand their pipelines through strategic acquisitions and internal innovation. At the same time, the FDA has approved more than 42 drugs in 2025 alone, signaling a robust regulatory environment that is benefiting well-positioned biotech companies.
Adding to this momentum, the Trump administration reached pricing agreements with major players including Gilead, Amgen, Merck, and Novartis, providing much-needed policy clarity and reducing uncertainty around drug pricing reform. Analysts at Barclays have described pharma as “a relatively safe haven in times of uncertainty,” with the sector expected to attract renewed investor attention through 2026.
Merck: Navigating the Keytruda Patent Cliff
Merck (MRK) remains one of the most discussed names in large-cap pharma. Its blockbuster cancer therapy, Keytruda (pembrolizumab), is the company’s crown jewel — but its patent exclusivity is set to expire later this decade, creating enormous revenue pressure. In response, Merck has been actively scouting large-scale acquisitions in the immunology and metabolic sectors to diversify its revenue streams ahead of this cliff. Barclays rated Merck as Overweight, citing expectations for earnings upside and potential multiple expansion driven by upcoming clinical readouts and new drug launches.
Bristol-Myers Squibb: Pipeline Green Shoots Emerging
Bristol-Myers Squibb (BMY) faces its own patent pressure with Eliquis approaching loss of exclusivity. However, analysts are increasingly optimistic about the company’s evolving pipeline. Barclays analysts noted that “green shoots from the company’s pipeline are starting to emerge,” supporting an Overweight rating for BMS. The company has also doubled down on cell therapy with its $1.5 billion acquisition of Orbital Therapeutics, securing OTX-201, a circular RNA therapy being developed for B cell-driven autoimmune disorders. This deal deepens BMS’ roots in next-generation therapies alongside its approved products Abecma and Breyanzi.
Amgen: A Defensive Giant With Bold Moves
Amgen (AMGN) has long been considered a defensive biotech holding, offering a solid dividend of approximately 3% and steady earnings backed by mature biologics like Enbrel, Prolia, and Xgeva. However, the company has shown it is not content to rest on its laurels. Amgen kicked off 2026 with the $840 million acquisition of Dark Blue Therapeutics, bolstering its oncology and metabolic capabilities. Its earlier $27.8 billion acquisition of Horizon Therapeutics added a portfolio of high-growth rare disease drugs, setting Amgen up for meaningful revenue growth through 2025 and beyond. Barclays initiated Amgen at Equal Weight, recognizing its stability while monitoring pipeline progress.
Gilead Sciences: Transforming HIV and Oncology
Gilead Sciences (GILD) is undergoing one of the most significant transformations in its history. Traditionally known as a virology powerhouse, Gilead is aggressively expanding into oncology and immunology. Its HIV franchise continues to lead the market with Biktarvy as the top daily pill for HIV treatment, while the landmark launch of lenacapavir — a twice-yearly injectable for PrEP — has set a new benchmark for long-acting HIV prevention. Gilead is also deepening its use of machine learning and AI in viral research to predict viral evolution and optimize clinical trial portfolios. A successful oncology trial readout could significantly re-rate the stock, making it one of the more compelling risk-reward opportunities in the sector.
Key Industry Trends Shaping the Sector
Several macro trends are driving momentum across the biotech and pharma landscape:
AI-Driven Drug Discovery is reshaping how companies identify and develop new therapies, potentially shortening the drug development timeline from 14 years to just 6–9 years.
M&A Acceleration saw venture-backed biotech acquisitions reach $64 billion in total deal value in 2025, with competition intensifying for high-value assets in obesity, oncology, and rare diseases.
Patent Cliff Pressures are forcing companies including Merck and Bristol-Myers Squibb to diversify portfolios aggressively through strategic deals and internal pipeline development.
FDA Approvals continue at a healthy pace, with more than 42 drugs approved in 2025, boosting biotech valuations and investor sentiment.
Policy Clarity from pricing agreements between the Trump administration and major pharma companies has substantially reduced regulatory tail risk, encouraging both investment and dealmaking.
Final Takeaway for Investors
The biotech and pharma sector in 2025 and 2026 presents a compelling mix of defensive stability and high-growth opportunity. Merck, Bristol-Myers Squibb, Amgen, and Gilead Sciences are navigating patent cliffs, pipeline development, and strategic acquisitions with varying degrees of momentum. Investors who monitor pipeline readouts, M&A activity, and FDA approval milestones will be best positioned to identify which biotech stocks offer the strongest near-term and long-term upside.
